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Abstract
Purpose The CONDOR study showed that docetaxel/cisplat-
in/5-fluorouracil (TPF) followed by conventional radiothera-
py with cisplatin 100 mg/m2 on days 1, 22, and 43 (cis100 +
RT; n = 27)) versus accelerated radiotherapy with cisplatin
weekly 40 mg/m2 (cis40 + ART; n = 29) in locally advanced
head and neck cancer (LAHNC) patients was not feasible.
Here, we report the analysis of health-related quality of life
(HRQOL) of the patients entered in this study.
Methods HRQOL was assessed at baseline, after two TPF,
before start of chemoradiotherapy, and 1, 4, 8, 12, and
24 months after completion of chemoradiotherapy using the
EORTC-QLQ-C30 and QLQ-H&N35 in 62 patients.
Results Compliance with the QOL questionnaires was 94%
(59/62) at baseline and 61% (30/49) at 12 months, respective-
ly. HRQOL decreased after TPF and further decreased during
chemoradiohteray in both arms equally. Pain and swallowing
dysfunction improved significantly during TPF but deteriorat-
ed below baseline levels during chemoradiotherapy, cis40 +
ART > cis100 + RT (p < 0.05). HRQOL and symptoms re-
stored to baseline within 12months in both arms and remained
at that level until 24 months.
Conclusions After TPF, cis40 + ART had a larger negative
impact on symptoms than cis100 + RT, probably due to the
ART. HRQOL and symptoms restored to baseline levels with-
in 12 months after end of treatment in both arms, which is an
important perspective for patients during the phase of most
serious acute side effects of treatment.
Trial registration: NCT00774319.
Keywords Quality of life . Symptoms . Locally advanced
head and neck cancer . Induction chemotherapy .
Chemoradiotherapy
Introduction
In patients with locally advanced head and neck cancer
(LAHNC), both disease and treatment have a great impact
on quality of life (QOL). Standard treatment for these patients
is concomitant chemoradiotherapy, which induces severe
acute and late toxicities. Common acute toxicities of chemo-
radiotherapy include mucositis, dermatitis, dysphagia, ototox-
icity, and polyneuropathy. Late toxicity may consist of
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dysphagia sometimes with aspiration, odynophagia,
xerostomia, fibrosis, and occasionally osteoradionecrosis [1,
2]. These toxicities negatively influence the QOL.
Induction chemotherapy, using docetaxel/cisplatin/5-fluo-
rouracil (TPF), has been proposed as a means to improve
outcome of patients with locally advanced head and neck can-
cer. There are only limited data on TPF followed by chemo-
radiotherapy using cisplatin. Although it is often stated that
neo-adjuvant TPF is well tolerated, the effect of the total reg-
imen, including the concomitant chemoradiation part, on
health-related quality of life (HRQOL) has not been reported
previously [3, 4]. HRQOL comprises physical and psychoso-
cial functioning, social interaction and disease- and treatment-
related symptoms. HRQOL was studied in LAHNC patients
receiving neo-adjuvant TPF versus PF followed by radiother-
apy alone, showing a trend towards a better HRQOL during
treatment in favor of TPF [5]. Other studies in LAHNC pa-
tients treated with chemotherapy and radiotherapy showed a
pattern of decline of QOL and then return to baseline within
12months after end of treatment [6, 7]. There are no published
data of QOL in LAHNC patients treated with induction che-
motherapy later than 12 months after end of treatment.
We conducted a randomized phase II feasibility study, the
CONDOR study, on induction chemotherapy with TPF
followed by cisplatin-based concomitant chemoradiotherapy
in two different schedules [8]. Sixty-two fit LAHNC patients
started treatment with TPF. Of these patients, 56were random-
ized to treatment with concomitant chemoradiotherapy with
conventional chemoradiotherapy and cisplatin 100 mg/m2
three weekly (cis100 + RT) (27 patients) or concomitant
CRT with accelerated radiotherapy with weekly cisplatin
40 mg/m2 (cis40 + ART) (29 patients). Ninety-six percent of
the patients treated with cis100 + RT and 90% of the patients
treated with cis40 + ART experienced grade 3 toxicity (on the
Common Toxicity Criteria 3.0), whereas grade 4 toxicity oc-
curred in 15 versus 14% of the patients. Most common grades
3–4 toxicity during TPF was febrile neutropenia (18%).
During concomitant CRT, grades 3–4 toxicities were mucosi-
tis in 22 versus 57%, dysphagia in 26 versus 24%, and dehy-
dration in 26 versus 14%, of patients with cis100 + RT and
cis40 + ART, respectively. Both treatment schedules were
proven not to be feasible, since the total planned dosage of
cisplatin during the chemoradiotherapy could only be admin-
istered in 32% of all patients due to severe toxicity, leading to
early termination of inclusion into the study. Despite high
toxicity rates, efficacy was comparable with other studies
using induction chemotherapy. Response rate after TPF was
61%, and 2-year overall survival was 77% in patients treated
with cis100 + RTand 76% for those treated with cis40 + ART.
In this paper, we will focus on the HRQOL of patients
treated in this phase II study with TPF induction chemothera-
py followed by concomitant chemoradiotherapy, with empha-
sis on long-term follow-up outcome.
Methods
Trial design and participants
The CONDOR study was a randomized phase II feasibility
study on induction chemotherapy with TPF followed by
cisplatin-based concomitant chemoradiotherapy in two differ-
ent schedules. In this study, fit LAHNC patients, stage III or
IV with aWHO-performance score of 0–1 and age ≤ 65 years,
were included. Patients were between 18 and 65 years of age,
and adequate bone marrow, hepatic, and renal functions.
Exclusion criteria were active alcohol addiction, admission
for chronic obstructive pulmonary disease during the last
12 months, and weight loss of more than 10% during the last
3 months prior to study entry. Details on therapy schedules
and toxicity registration and grading were published recently
[8].
QOL assessment
QOL data were collected using the European Organization for
Research and Treatment of Cancer (EORTC) QOL question-
naire (QLQ-C30) version 3.0 and the EORTC head and neck
cancer module (HN-35) [2, 5, 9–11]. The EORTC QLQ-C30
contains a global HRQOL score, five functional scales (phys-
ical, role, cognitive, emotional, and social), three symptom
scales (fatigue, nausea/vomiting, and pain), and six single-
item scales (dyspnea, sleep disturbance, appetite loss, consti-
pation, diarrhea, and financial difficulties). The EORTC Head
and Neck module, the EORTC QLQ-H&N35 has been spe-
cifically designed and validated for head and neck cancer pa-
tients [11]. This is a 35-item questionnaire with seven symp-
tom scales (pain, swallowing, senses, speech, social eating,
social contact, and sexuality), six single-item scales (difficul-
ties of teeth, mouth opening, dry mouth, sticky saliva,
coughing, and feeling ill), and five items about the additional
use of painkillers, nutritional supplements, and feeding tube
and changes in body weight. All items were transformed to
scales from 0 to 100, according to the EORTC scoring manual
recommendations [12]. A high score on functional scale rep-
resents a better level of functioning, whereas a high score on a
symptom scale indicates more severe symptoms. Differences
of at least 10 points (on a scale of 0–100) on a mean value of
the HRQOL parameter were classified as clinically significant
[13]. Changes of ≥ 10 points are moderate, whereas changes
of ≥ 20 points on a mean score are classified as large. The
primary HRQOL analysis was based on preselected HRQOL
scores: global HRQOL, pain, swallowing, speech, and
coughing.
Patients completed the QOL questionnaires at baseline,
after 2 cycles of TPF, before start of concomitant chemoradio-
therapy (i.e., after 2, 3, or 4 TPF cycles) and 1, 4, 8, 12, 18, and
24 months after the end of chemoradiotherapy.
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Statistical analysis
HRQOL was a secondary endpoint of the CONDOR study;
power analysis was calculated on the primary endpoint, which
was feasible. Analyses were performed using SAS version 9.2
and SPSS version 20. Compliance rates were calculated as the
number of forms received divided by the number of forms
expected at each time point. Expected forms were from pa-
tients still alive at the given time point, regardless of disease
state. Fishers’ exact test was used to determine differences in
compliance between the treatment arms. One-sided t test was
used to compare the baseline quality-of-life results of the cur-
rent study with the EORTC reference values.
For the primary analyses, we used an Unstructured
Covariance Model to conduct separate repeated measures
analyses for each HRQOL outcome [14]. We included time,
treatment, and the interaction between time and treatment as
fixed factors in the linear mixed model. Time was treated as a
categorical variable to allow the model to fit every possible
pattern in time. The interaction between time and treatment
was only defined after the start of the chemoradiotherapy. In
addition, we added the baseline values of the dependent var-
iables as possible significant covariates to the model. Residual
plots from the mixed models were examined to assess model
assumptions. All linear mixedmodel analyses were performed
on all participants, including those with incomplete datasets.
Differences between treatments at specific time moments
were estimated from the mixed model. Two-tailed analyses
were performed with a p value of 0.05.
Moreover, sensitivity analysis using the proportion of pa-
tients experiencing an improvement/worsening of more than
10 or 20 points in each selected scale was performed [13].
Results
Participants
Patient characteristics are shown in Table 1. A CONSORT
diagram is added as eFig. 1.
QOL: compliance
Data of all patients were included in this analysis. Compliance
to the questionnaires was 94% at baseline, 71% after 2 TPF,
70% before start of chemoradiotherapy, 61% after chemora-
diotherapy, 63% after 4 months, 66% after 12 months, 68%
after 18 months, and 62% after 24 months of follow-up.
Compliance was significantly lower in patients treated with
cis40 + ART at 4 months after end of treatment, 45 versus
81%, respectively (p = 0.006). At all other time points com-
pliance between the two treatment arms was similar.
QOL baseline scores
Baseline QOL scores were compared with the reference
values of head and neck cancer patients, stage III–IV diseases
(eTable 1), provided by the EORTC [15]. All EORTC head
Table 1 Patient characteristics
Total = 62 pts Cis100 + RT = 27 pts Cis40 + ART = 29 pts
N (%) N (%) N (%)
Sex
Male 50 (80.6) 17 (63) 27 (93.1)
Female 12 (19.4) 10 (37) 2 (6.9)
Age (years)
Mean 53.4 54.0 53.2
Range 27–65 32–65 27–64
WHO performance status
0 49 (79) 23 (85.2) 23 (79.3)
1 13 (21) 4 (14.8) 6 (20.7)
Tumor site
Oral cavity 12 (19.4) 4 (14.8) 6 (20.7)
Oropharynx 37 (59.7) 18 (66.7) 16 (55.2)
Hypopharynx 8 (12.9) 3 (11.1) 5 (17.2)
Larynx 5 (8.1) 2 (7.4) 2 (6.9)
Disease stage
III 5 (8.1) 2 (7.4) 3 (10.3)
IV 57 (91.9) 25 (92.6) 26 (89.7)
Abbreviations: pts, patients; Cis100 + RT, cisplatinum 100 mg/m2 with conventional radiotherapy; Cis40 + ART,
cisplatinum 40 mg/m2 with accelerated radiotherapy
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and neck reference data are based on pretreatment HRQOL. A
clinically and statistically significant difference in baseline
scores of our patients compared with the EORTC reference
values was found on global HRQOL (75.3 versus 63.3,
p < 0.001) and physical function (92.0 versus 81.2,
p < 0.001), and on the symptom scores sexuality (14.2 versus
32.2, p < 0.001), dry mouth (15.3 versus 31.1, p < 0.001),
sticky saliva 19.5 versus 32.4, p < 0.001), coughing (18.6
versus 34.9, p < 0.001), feeling ill (12.4 versus 21.7,
p = 0.003), and feeding tube (5.1 versus 18.3, p < 0.001), in
Table 2 Mean scores over time at baseline, after two TPF, after chemoradiotherapy
Baseline (59/
62)
After 2 TPF (42/
59)
After CRT cis100 + RT (18/
27)
After CRT cis40 + ART (16/
29)
Difference between
groups CRT (p value)
Mean SD Mean SD Mean SD Mean SD
EORTC QLQ-30
Global health status 75.3 19.7 70.1 11.5 44.9 11.9 46.1 12.0 0.85
Physical function 92.0 15.1 80.5a 11.2 61.0 11.5 58.4 11.6 0.60
Role function 86.1 23.8 59.6a 15.2 45.0 15.9 36.0 16.2 0.32
Emotional function 74.7 21.4 84.9a 12.3 84.9 12.3 77.6 12.8 0.61
Cognitive function 91.7 15.2 87.6 18.0 70.2 18.2 67.4 18.3 0.61
Social function 87.5 18.1 79.6 14.5 66.4 14.9 67.1 15.1 0.91
Fatigue 20.8 20.9 35.7a 10.6 50.6 11.2 60.8 11.5 0.97b
Nausea/vomiting 2.5 8.6 8.6 5.4 30.9 6.0 37.6 6.3 0.20
Pain 25.6 29.7 11.0a 14.6 33.8 15.0 49.2 15.3 0.043b
Dyspnoea 6.7 14.7 9.0 11.2 16.0 11.4 19.9 11.6 0.45
Insomnia 25.0 27.9 18.1 11.6 27.6 12.1 27.5 12.3 0.99
Appetite loss 17.2 27.8 22.8 17.5 50.2 18.1 62.2 18.3 0.19b
Constipation 12.2 24.5 11.4 5.6 20.6 6.5 32.0 6.9 0.08b
Diarrhea 2.2 8.4 12.9a 8.8 8.1 9.1 10.5 9.3 0.63
Financial problems 13.3 26.2 11.4 16.9 8.3 17.2 25.0 17.3 0.011b
EORTC QLQ-H&N 35
Pain 27.2 22.5 14.5a 11.9 38.1 12.2 55.7 12.3 0.003b
Swallowing 24.9 25.1 9.7a 10.8 43.3 11.3 59.9 11.4 0.0101b
Senses 10.5 21.0 21.7a 15.2 45.0 15.6 47.3 15.8 0.74
Speech 18.1 21.3 10.9 7.9 27.1 8.5 44.8 8.7 0.004b
Social eating 21.9 26.0 15.3 14.3 41.4 14.6 39.9 14.8 0.82
Social contact 5.6 14.9 7.9 6.8 12.9 7.0 9.5 7.0 0.29
Sexuality 14.2 25.2 33.3a 19.4 53.9 20.0 55.0 20.1 0.90
Teeth 19.1 27.2 6.3a 14.1 10.4 14.5 15.2 14.9 0.53
Opening mouth 25.4 34.1 13.3a 16.8 27.2 17.3 31.5 17.4 0.58
Dry mouth 15.3 24.2 25.3a 18.2 44.4 18.7 56.8 18.9 0.14b
Sticky saliva 19.5 31.2 20.5 20.2 57.5 20.6 66.3 20.8 0.32
Coughing 18.6 25.0 14.4 12.3 31.8 12.8 45.3 13.0 0.076b
Feeling ill 12.4 21.4 19.8 26.6 48.1 32.8 47.9 32.1 0.98
Pain killers 61.0 49.2 41.2a 24.9 95.6 25.9 83.5 26.3 0.40b
Nutritional support 31.0 46.7 19.7a 18.5 83.0 19.6 66.0 20.0 0.20b
Feeding tube 5.1 22.2 4.8 15.7 52.3 16.6 85.0 17.0 0.003b
Weight loss 43.9 50.0 15.2a 14.6 81.3 16.1 33.3 17.1 0.0009b
Weight gain 17.9 38.6 50.8a 21.8 26.3 23.4 19.3 24.6 0.70
Abbreviations: cis100 + RT, cisplatin 100mg/m2 on days 1, 22, and 43 in combinationwith conventional radiotherapy; cis40 +ART, cisplatin 40mg/m2
weekly in combination with accelerated radiotherapy; EORTC, European Organization for Research and Treatment of Cancer; QLQ-C30, Quality of
Life Questionnaire C30; QLQ-HN-35, Head and Neck Cancer-Specific Module
a Clinically significant difference (10 points or more) after 2 TPF compared to baseline
b Clinically significant difference (10 points or more) between treatment arms after CRT
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favor of the patients in our study. This indicates that in terms
of QOL a relatively favorable (i.e., fit) patient group was se-
lected for this study.
QOL during TPF
Global HRQOL decreased non-significantly after 2 TPF
(70.1) and even more after the end of TPF (64.0)
(Table 2; Fig. 1). Pain and swallowing problems both
decreased with more than 10 points after 2 TPF, but both
increased before start of chemoradiotherapy (Table 2;
Fig. 2). Speech problems and coughing improved non-
significantly after two TPF, but deteriorated at the end of
TPF (Table 2; Fig. 2).
QOL: differences between treatment arms
during chemoradiotherapy and changes over time
Global HRQOL decreased during chemoradiotherapy,
equally in both arms (Table 2; Fig. 1). Four months after
end of treatment, global HRQOL increased and it was
restored to baseline levels within 12 months after end
of treatment. Beyond 12 months however, patients treat-
ed with cis100 + RT had a higher score than the patients
treated with cis40 + ART, albeit not significant. Twenty-
four months after end of treatment global HRQOL was
equal in both arms (Table 3). Pain, swallowing problems,
speech problems and coughing all worsened during che-
moradiotherapy. A clinically and statistically significant
difference between the treatment arms at end of treatment
was found in all these symptom scores in favor of the
patients treated with cis100 + RT (Table 2; Fig. 2). In
both treatment arms, pain, swallowing problems, and
speech problems recovered to baseline level 4 months
after treatment. There were no differences in mean scores
of pain, swallowing problems, speech problems, and
coughing between the treatment arms at 12 and
24 months after end of treatment (Table 3).
Other HRQOL scales
All other HRQOL items were analyzed on an exploratory
basis. Patients treated with cis40 + ART scored clinically
and statistically significantly worse on feeding tube depen-
dence after CRT but significantly better on nutritional support
and use of painkillers. Patients treated with cis100 + RTscored
clinically and statistically significant worse on weight loss.
Moreover, a clinically significant difference (> 10 points)
was found for fatigue, appetite loss, constipation, and dry
mouth in favor of cis100 + RT.
Furthermore, after 2 years follow-up patients treated with
cis100 + RT had clinically significant (> 10 points) better
cognitive function and less sticky saliva compared with pa-
tients treated with cis40 + ART. Patients treated with cis40 +
ART scored clinically significant worse on nutritional support
and feeding tube than patients in arm cis100 + RT (Table 3).
Sensitivity analyses
The proportion of patients experiencing an improvement or
worsening of 10 or 20 points on the selected scales between
baseline and end of chemoradiotherapy were compared be-
tween the treatment arms. These analyses showed the same
trend of more pain in patients treated with cis40 + ART com-
pared with cis100 + RT (Table 4). Moreover, a higher percent-
age of patients experienced a worsening in speech and
swallowing problems in the group treated with cis40 + ART,
whereas more patients experienced improvement in the group
treated with cis100 + RT (Table 4).
Discussion
HRQOL was assessed as secondary endpoint of the ran-
domized phase II CONDOR study in patients with locally
advanced head and neck cancer treated with TPF induction
chemotherapy followed by cisplatin 100 mg/m2 with con-
ventional radiotherapy versus cisplatin 40 mg/m2 with ac-
celerated radiotherapy. Our study patients had a clinically
Fig. 1 Mean Global Health Scores over time by treatment arm
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and statistically significant better global HRQOL and
physical function compared with the EORTC reference
values for head and neck cancer patients with stage III-IV
disease, which data were obtained during standard treat-
ment [15]. Global HRQOL in our patients was also better
than the patients included in the EORTC 24971/TAX 323
study [5]. This is a reflection of our selection criteria to
include only very fit LAHNC patients, i.e., no admissions
for COPD in the past year, WHO 0–1, no weight loss more
than 10% in the past 3 months, no active alcohol addiction,
and adequate bone marrow, liver, and kidney functions.
Despite the excellent clinical condition of our patients at
baseline reflected by the good global HRQOL, both treat-
ment schedules were shown not feasible [8].
Global HRQOL declined during TPF and more during
chemoradiotherapy, without any difference between the
two treatment arms. The declining global HRQOL is in
contrast with the results of the EORTC 24971/TAX 323
study, where global HRQOL improved during TPF [5]. In
that study however, baseline global HRQOL was signifi-
cantly lower than in our study (61.2 versus 75.3, respec-
tively, p < 0.001). After 2 cycles of TPF though, global
HRQOL scores in the CONDOR and TAX 323 cohorts
were comparable, 70.1 and 69.3, respectively. However,
before start with CRT the global HRQOL scores of the
CONDOR cohort decreased further (64.0) while the TAX
323 cohort remained stable (70.7; p < 0.05). This is in
agreement with Tribius et al. who reported a significant
greater deterioration in global HRQOL in patients with
the highest baseline scores [16].
Global HRQOL restored to baseline levels within
12 months after end of treatment and remained at that
level after 24 months. This is in line with other QOL in
head and neck cancer studies [6, 9, 17] and is not very
satisfying, because an improvement in Qol is desirable in
cured patients. This pattern of no improvement in quality
of life could be hypothetically caused by substitution of
tumor-associated complaints at presentation by therapy
sequelae-associated complaints leading to high symptom
scores after the end of treatment [18]. Other studies
concerning induction chemotherapy in head and neck can-
cer did not include QOL analysis [19–21].
In contrast to the declining global HRQOL scores, we
found improvement of symptom scores, especially for
pain and swallowing problems during TPF. This is in line
with the results of the EORTC 24971/TAX 323 study [5]
and presumably reflects tumor response, which is consis-
tent with our efficacy results; 62% of the patients had
Fig. 2 Mean symptom scores over time by treatment arm: a pain, b coughing, c speech problems, and d swallowing problems
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partial or complete responses after TPF. The improvement
in pain and swallowing problems did not lead to better
global health. Probably, the increase of other symptom
scores such as fatigue, constipation, and feeling ill plays
a role in declining global health score.
Patients in the CONDOR study showed differences in phy-
sician rated toxicity scores of mucositis and dysphagia be-
tween the two treatment arms, showing more grades 3 and 4
mucositis in the patients treated with cis40 + ART (59 versus
26%). The differences in symptom scores on speech
Table 3 Mean scores over time at baseline, and after 1 and 2 years after treatment
1-year follow-up
cis 100 + RT
1-year follow-up
cis 40 + ART
Difference between
groups (p value)
2-year follow-up
cis 100 + RT
2-year follow-up
cis 40 + ART
Difference between
groups (p value)
Mean SD Mean SD Mean SD Mean SD
EORTC QLQ-30
Global health status 84.0 9.9 71.4 24.1 0.07a 80.6 16.4 76.2 23.8 0.64
Physical function 91.3 10.7 85.1 16.1 0.22 92.8 7.8 88.6 11.4 0.35
Role function 87.2 15.4 73.5 37.7 0.19a 83.3 22.5 73.8 30.2 0.44
Emotional function 91.0 10.5 78.6 24.9 0.09a 83.3 25.1 88.1 16.6 0.66
Cognitive function 93.6 8.4 81.3 25.7 0.09a 88.9 16.4 69.0 33.9 0.19b
Social function 91.0 12.9 81.3 29.7 0.28 93.1 13.2 88.1 15.9 0.47
Fatigue 16.2 17.9 23.5 24.5 0.37 22.2 21.7 28.6 31.3 0.61
Nausea/vomiting 0.0 0.0 3.92 11.1 0.16 0.0 0.0 7.1 18.9 0.36
Pain 5.1 10.5 16.7 30.0 0.16a 8.3 16.7 7.1 18.9 0.89
Dyspnoea 2.6 9.2 13.7 20.6 0.08a 2.8 9.6 9.5 16.3 0.35
Insomnia 2.6 9.2 17.6 20.8 0.02a 11.1 21.7 14.3 17.8 0.75
Appetite loss 7.7 20.0 17.6 26.7 0.25 5.6 13.0 14.3 26.2 0.44
Constipation 0.0 0.0 11.8 20.2 0.046a 5.6 13.0 0.0 0.0 0.17
Diarrhea 0.0 0.0 2.1 8.3 0.33 0.0 0.0 4.8 12.6 0.36
Financial problems 10.3 16.0 14.6 29.7 0.62 0.0 0.0 4.8 12.6 0.36
EORTC QLQ-H&N 35
Pain 8.3 10.8 14.7 17.3 0.23 7.4 10.5 12.5 11.8 0.33
Swallowing 4.5 8.1 12.7 15.9 0.08 4.9 8.3 11.5 12.5 0.17
Senses 17.9 17.3 17.6 21.6 1.00 16.7 26.6 12.5 7.7 0.62
Speech 4.3 9.7 13.7 20.6 0.11 0.9 3.2 6.9 8.3 0.08
Social eating 10.9 11.0 19.1 24.6 0.19 6.9 12.7 17.7 22.0 0.18b
Social contact 0.5 1.8 7.3 14.8 0.23 0.6 1.9 1.7 4.7 0.47
Sexuality 12.5 16.1 27.8 26.5 0.09a 11.1 17.9 13.9 16.4 0.75
Teeth 2.6 9.2 14.6 27.1 0.11a 5.6 13.0 8.3 23.6 0.74
Opening mouth 12.8 16.9 15.7 20.8 0.69 13.9 22.3 20.8 24.8 0.52
Dry mouth 43.6 21.0 49.0 29.1 0.58 33.3 24.6 41.7 23.6 0.46
Sticky saliva 17.9 22.0 31.3 28.5 0.18a 16.7 22.5 37.5 21.4 0.05b
Coughing 10.3 16.0 15.7 23.9 0.49 8.3 15.1 8.3 15.4 1.00
Feeling ill 2.6 9.2 17.6 31.4 0.08a 8.3 20.7 4.2 11.8 0.61
Pain killers 7.7 27.7 23.5 43.7 0.24a 16.7 38.9 25.0 46.3 0.67
Nutritional support 15.4 37.6 23.5 43.7 0.60 0.0 0.0 12.5 35.4 0.35b
Feeding tube 0.0 0.0 5.9 24.3 0.39 0.0 0.0 12.5 35.4 0.35b
Weight loss 0.0 0.0 25.0 44.7 0.04a 8.3 28.9 12.5 35.4 0.78
Weight gain 46.2 51.9 31.3 47.9 0.43a 41.7 51.5 25.0 46.3 0.47b
Abbreviations: cis100 + RT, cisplatin 100mg/m2 on days 1, 22, and 43 in combinationwith conventional radiotherapy; cis40 +ART, cisplatin 40mg/m2
weekly in combination with accelerated radiotherapy; EORTC, European Organization for Research and Treatment of Cancer; QLQ-C30, Quality of
Life Questionnaire C30; QLQ-HN-35, Head and Neck Cancer-Specific Module
a Clinically significant difference (10 points or more) 1 year after treatment between treatment arms
b Clinically significant difference (10 points or more) between treatment arms after 2 years
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problems, swallowing problems and pain in favor of the pa-
tients treated with cis100 + RT are in line with this. As de-
scribed earlier, the difference in mucositis can be explained by
the toxicity caused by accelerated radiotherapy and theweekly
radio-sensitizing effect of cisplatin [8, 22]. High toxicity rates
were observed with this treatment schedule, causing increas-
ing symptom scores and decreasing global HRQOL during
treatment. Despite this, all symptom scores in both treatment
arms returned to baseline level at 12 months after end of
treatment.
The main limitations of this study are the relatively
small patient population and the difference in compliance
between the two treatment arms at 4 months after chemo-
radiotherapy namely 45% versus 81% in cis40 + ART and
cis100 + RT respectively. This difference in compliance
rate at 4 months could have led to selection bias, since
patients treated with cis40 + ART experienced more tox-
icity during chemoradiotherapy and had worse symptom
scores. Assuming that the patients treated with cis40 +
ART who had more symptoms were less likely to return
Table 4 Sensitivity analysis:
proportion of patients
experiencing improvement/
worsening of selected scales after
chemoradiotherapy compared
with baseline
Cis100 + RT (N = 27) N
(%)
Cis40 + ART (N = 29) N
(%)
p value for
difference
Global qualiy of lifea
≥ 16.6 points worsening 15 (83.3) 10 (71.4) 0.669
≥ 25 points worsening 13 (72.2) 8 (57.1) 0.465
≥ 16.6 points
improvement
0 (0) 1 (7.1) 0.437
≥ 25 points
improvement
0 (0) 0 1.00
Coughingb
≥ 33.3 points worsening 10 (58.8) 8 (57.1) 1.00
≥ 33.3 points
improvement
3 (17.6) 3 (21.4) 1.00
Painc
≥ 11.1 points worsening 8 (47.1) 12 (85.7) 0.057
≥ 22.2 points worsening 7 (41.2) 11 (78.6) 0.067
≥ 11.1 points
improvement
4 (23.5) 2 (14.3) 0.664
≥ 22.2 points
improvement
2 (11.8) 1 (7.1) 1.00
Speech problemsd
≥ 11.1 points worsening 8 (47.1) 10 (71.4) 0.275
≥ 22.2 points worsening 6 (35.3) 8 (57.1) 0.289
≥ 11.1 points
improvement
5 (29.4) 2 (14.3) 0.412
≥ 22.2 points
improvement
4 (23.5) 2 (14.3) 0.664
Swallowinge
≥ 11.1 points worsening 12 (70.6) 11 (78.6) 0.698
≥ 22.2 points worsening 11 (64.7) 10 (71.4) 1.00
≥ 11.1 points
improvement
4 (23.5) 2 (14.3) 0.664
≥ 22.2 points
improvement
3 (17.6) 1 (7.1) 0.607
Abbreviations: cis100 + RT, cisplatin 100 mg/m2 on days 1, 22, and 43 in combination with conventional
radiotherapy; cis40 + ART, cisplatin 40 mg/m2 weekly in combination with accelerated radiotherapy
aGlobal QoL score may take all values from 0 to 100 distance by 8.3 points (0, 8.3, 16.6, and so on). A shift of
more than 10 points means a shift of 16.6 points or more. A shift of more than 20 points means a shift of 25 points
or more
b Coughing score may take all values from 0 to 100 distance by 33.3 points (0, 33.3, 66.6, and so on)
c Pain score may take all values from 0 to 100 distance by 2.8 points
d Speech score may take all values from 0 to 100 distance by 5.5 points
e Swallowing score may take all values from 0 to 100 distance by 2.8 points
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the questionnaires, possibly the QoL scores at 4 months
for this group are overestimated.
Our study has several strengths. It has a randomized
design, and it is the first study reporting on QOL in pa-
tients treated with induction chemotherapy followed by
concomitant cisplatin-based chemoradiotherapy. Because
we used standard and validated questionnaires, compari-
son of our results with other studies in locally advanced
head and neck cancer is possible. Overall compliance in
our study was high, with more than 60% returned ques-
tionnaires during treatment as well as after 1 and 2 years
after end of treatment. This is much higher than the com-
pliance rate of 45% after 9 months in the EORTC 24971/
TAX 323 study [5].
In summary, in our patients with locally advanced
head and neck cancer, we found high baseline HRQOL
scores. However, despite this initial high global health
score, reflecting the good condition of the patients par-
ticipating in the CONDOR study, both chemoradiation
treatment schedules after prior TPF chemotherapy were
shown not feasible. Especially patients treated with
cis40 + ART experienced high rates of grades 3 and 4
mucositis and consequently high symptom scores (pain,
swallowing problems, and feeding tube dependence) dur-
ing treatment.
Importantly, global health and all the symptom scores
restored to baseline levels within 12 months after end of
treatment in both arms and remained at that level at
2 years of follow-up after end of treatment. This is re-
markable given the impressive toxicity the patients have
gone through, and important with regard to the quality of
the survivorship of these patients who presented with such
advanced localized head and neck carcinomas.
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